SANTA ANA, Calif.—Johnson & Johnson Vision announced on Feb. 2 that the U.S. Food and Drug Administration (FDA) approved the Tecnis Eyhance and Tecnis Eyhance Toric II intraocular lens (IOL) for the treatment of cataract patients in the U.S. The next generation monofocal lenses are designed for patients with or without astigmatism. The first implantation of Tecnis Eyhance IOL in the U.S. will happen in Texas next week, Johnson & Johnson Vision said. “Built on the proven Tecnis platform, Tecnis Eyhance combines low-light performance with breakthrough refractive surface design, providing a new kind of monofocal experience for cataract patients,” said Rajesh K. Rajpal, MD, chief medical officer and global head of clinical and medical affairs at Johnson & Johnson Vision.

“Additionally, the Tecnis Eyhance Toric II lens is engineered with a new squared and frosted haptic design for added friction inside the capsular bag to treat cataract patients with astigmatism.”

Tecnis Eyhance first launched in Europe in February 2019 and became commercially available in Latin America and Canada in the summer of 2020. Tecnis Eyhance and Tecnis Eyhance Toric II are now commercially available in the U.S., with Tecnis Eyhance Toric II launching in Europe and Canada later this year.